Takeda Pharmaceutical (TKDA) Stock Overview

Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. More details

TKDA fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	0/6
Financial Health	4/6
Dividends	4/6

Rewards

Trading at 65.5% below our estimate of its fair value

Earnings are forecast to grow 38.57% per year

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt

Dividend of 3.81% is not well covered by earnings

TKDA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW497,995 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

497,995 investors already sharing narratives

View all narratives

Takeda Pharmaceutical Company Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Takeda Pharmaceutical
Historical stock prices
Current Share Price	JP¥14.50
52 Week High	JP¥16.10
52 Week Low	JP¥11.30
Beta	0.088
1 Month Change	10.69%
3 Month Change	-7.05%
1 Year Change	13.28%
3 Year Change	4.32%
5 Year Change	3.57%
Change since IPO	-15.94%

Recent updates

Shareholder Returns

	TKDA	DE Pharmaceuticals	DE Market
7D	5.1%	6.1%	4.1%
1Y	13.3%	57.0%	2.9%

Return vs Industry: TKDA underperformed the German Pharmaceuticals industry which returned 57% over the past year.

Return vs Market: TKDA exceeded the German Market which returned 2.9% over the past year.

Price Volatility

Is TKDA's price volatile compared to industry and market?
TKDA volatility
TKDA Average Weekly Movement	3.5%
Pharmaceuticals Industry Average Movement	5.6%
Market Average Movement	5.6%
10% most volatile stocks in DE Market	12.5%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: TKDA has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: TKDA's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1781	47,029	Julie Kim	www.takeda.com

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands.

Takeda Pharmaceutical Company Limited Fundamentals Summary

How do Takeda Pharmaceutical's earnings and revenue compare to its market cap?
TKDA fundamental statistics
Market cap	€45.87b
Earnings (TTM)	-€825.67m
Revenue (TTM)	€24.41b

1.9x

P/S Ratio

-55.6x

P/E Ratio

Is TKDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TKDA income statement (TTM)
Revenue	JP¥4.51t
Cost of Revenue	JP¥1.62t
Gross Profit	JP¥2.89t
Other Expenses	JP¥3.04t
Earnings	-JP¥152.39b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 30, 2026

Earnings per share (EPS)	-96.46
Gross Margin	64.06%
Net Profit Margin	-3.38%
Debt/Equity Ratio	65.7%

How did TKDA perform over the long term?

See historical performance and comparison

Dividends

3.8%

Current Dividend Yield

-207%

Payout Ratio

Does TKDA pay a reliable dividends?

See TKDA dividend history and benchmarks

When do you need to buy TKDA by to receive an upcoming dividend?
Takeda Pharmaceutical dividend dates
Ex Dividend Date	Mar 31 2026
Dividend Pay Date	Jul 06 2026
Days until Ex dividend	98 days
Days until Dividend pay date	1 day

Does TKDA pay a reliable dividends?

See TKDA dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/06 21:46
End of Day Share Price	2026/07/03 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Takeda Pharmaceutical Company Limited is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Takeda Pharmaceutical (TKDA) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Takeda Pharmaceutical Company Limited Competitors

Bayer

Merck KGaA

Dermapharm Holding

PEPTONIC medical

Price History & Performance

Recent News & Updates

Takeda Pharmaceutical Company Limited Announces Management and Committee Changes

Takeda Pharmaceutical Company Limited Presents Additional Results from Two Pivotal Studies Showing Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep for People with Narcolepsy Type 1

Takeda Announces Positive Topline Results for Phase 3 Study Comparing Zasocitinib to Deucravacitinib in Adults with Moderate-To-Severe Plaque Psoriasis

Takeda Pharmaceutical Company Limited to Report Q2, 2027 Results on Oct 29, 2026

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 24, 2026

Takeda Pharmaceutical Company Limited Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of TAK-881 In Primary Immunodeficiency Disease

Recent updates

Takeda Pharmaceutical Company Limited Announces Management and Committee Changes

Takeda Pharmaceutical Company Limited Presents Additional Results from Two Pivotal Studies Showing Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep for People with Narcolepsy Type 1

Takeda Announces Positive Topline Results for Phase 3 Study Comparing Zasocitinib to Deucravacitinib in Adults with Moderate-To-Severe Plaque Psoriasis

Takeda Pharmaceutical Company Limited to Report Q2, 2027 Results on Oct 29, 2026

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 24, 2026

Takeda Pharmaceutical Company Limited Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of TAK-881 In Primary Immunodeficiency Disease

Takeda Pharmaceutical Company Limited Announces Zasocitinib Delivers Rapid and Durable Skin Clearance in Plaque Psoriasis

Takeda Pharmaceutical Company Limited Announces Board and Executive Retirements

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Takeda Pharmaceutical Company Limited to Report Q1, 2027 Results on Jul 30, 2026

Takeda and Protagonist Therapeutics, Inc Announce FDA Accepts Priority Review for First-In-Class Therapy Rusfertide in Polycythemia Vera

Takeda Announces Positive Phase 3 Data Demonstrate Potential for ENTYVIO®? (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda Pharmaceutical Company Limited's Oveporexton (TAK-861) as A Potential First-In-Class Therapy for Narcolepsy Type 1

Takeda Pharmaceutical Company Limited Revises Consolidated Earnings Guidance for the Fiscal Year 2025

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-To-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda Pharmaceutical Company Limited to Report Q3, 2026 Results on Jan 29, 2026

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Takeda Presents New Data Showing Mezagitamab Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Takeda Inc. Announces Completion of the 7-Year Pivotal Phase 3 Tides Trial Evaluating Its Dengue Vaccine, Qdenga®?V

Takeda Pharmaceutical Company Limited Declares Dividend for Second Quarter-End of Fiscal Year Ending March 31, 2026, Payable on December 1, 2025

Takeda Inc. Announces the Recently FDA- Approved Hyhub and Hyhub Duo Devices Now Available in the U.S. to Simplify Hyqvia® Infusion Preparation

Takeda Announces Executive Changes, Effective June 2026

Takeda Presents Orexin Data from Landmark Oveporexton Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda Announces U.S. FDA Approves Expanded Indication for VONVENDI for Adults and Children with Von Willebrand Disease

Takeda Pharmaceutical Company Limited to Report Q2, 2026 Results on Oct 30, 2025

Takeda Pharmaceutical Company Limited Announces an Embargoed Version of an Abstract for Phase 3 TAK-861-3002 Study (Radiantlight) of Oveporexton (TAK-861) in Narcolepsy Type 1, Which Is Slated to Be Presented At the Upcoming World Sleep 2025 Congress

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Fiscal Year 2025

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHub Duo Devices to Simplify HYQVIA Administration

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (Tak-861) in Narcolepsy Type 1

Takeda Pharmaceutical Company Limited Approves Dividend

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025

Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

European Commission Approves Adcetris®? (Brentuximab Vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage Iib/Iii/Iv Hodgkin Lymphoma in Combination with Ecadd

Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide

Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Takeda Pharmaceutical Company Limited Receives Approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli®? (Maralixibat) Oral Solution for the Treatment of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Japan

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera

Takeda Pharmaceutical Company Limited to Report Q1, 2026 Results on Jul 30, 2025

Takeda Pharmaceutical Company Limited (TSE:4502) announces an Equity Buyback for 28,500,000 shares, representing 1.8% for ¥100,000 million.

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL